Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension

George L. Bakris, R. D. Toto, P. A. McCullough

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion ≥30 and <299 mg/day). Albuminuria is a marker for development of nephropathy in type II diabetes and for increased cardiovascular morbidity and mortality. Recent studies have demonstrated the importance of antihypertensive agents that inhibit the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease. A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCI or benazepril HCI/hydrochlorothiazide. Other objectives include a comparison of the proportion of patients who progress to overt diabetic nephropathy and the safety of these two combination therapies in these high-risk patients.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalJournal of Human Hypertension
Volume19
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Albuminuria
Type 2 Diabetes Mellitus
Albumins
Diabetic Nephropathies
Hypertension
Amlodipine
Hydrochlorothiazide
Renin-Angiotensin System
Antihypertensive Agents
Chronic Kidney Failure
Disease Progression
Creatinine
Clinical Trials
Morbidity
Kidney
Safety
Mortality
Therapeutics
benazepril

Keywords

  • ACE inhibitor
  • Albuminuria
  • Calcium channel blocker
  • Diabetic nephropathy
  • End-stage renal disease
  • Microalbuminuria

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. / Bakris, George L.; Toto, R. D.; McCullough, P. A.

In: Journal of Human Hypertension, Vol. 19, No. 2, 02.2005, p. 139-144.

Research output: Contribution to journalArticle

@article{9f4083f03a52477c827a65a58e557f28,
title = "Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension",
abstract = "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion ≥30 and <299 mg/day). Albuminuria is a marker for development of nephropathy in type II diabetes and for increased cardiovascular morbidity and mortality. Recent studies have demonstrated the importance of antihypertensive agents that inhibit the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease. A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCI or benazepril HCI/hydrochlorothiazide. Other objectives include a comparison of the proportion of patients who progress to overt diabetic nephropathy and the safety of these two combination therapies in these high-risk patients.",
keywords = "ACE inhibitor, Albuminuria, Calcium channel blocker, Diabetic nephropathy, End-stage renal disease, Microalbuminuria",
author = "Bakris, {George L.} and Toto, {R. D.} and McCullough, {P. A.}",
year = "2005",
month = "2",
doi = "10.1038/sj.jhh.1001789",
language = "English (US)",
volume = "19",
pages = "139--144",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension

AU - Bakris, George L.

AU - Toto, R. D.

AU - McCullough, P. A.

PY - 2005/2

Y1 - 2005/2

N2 - Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion ≥30 and <299 mg/day). Albuminuria is a marker for development of nephropathy in type II diabetes and for increased cardiovascular morbidity and mortality. Recent studies have demonstrated the importance of antihypertensive agents that inhibit the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease. A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCI or benazepril HCI/hydrochlorothiazide. Other objectives include a comparison of the proportion of patients who progress to overt diabetic nephropathy and the safety of these two combination therapies in these high-risk patients.

AB - Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). The early stage of nephropathy is manifested by the presence of low levels of urinary albumin (microalbuminuria or urinary albumin excretion ≥30 and <299 mg/day). Albuminuria is a marker for development of nephropathy in type II diabetes and for increased cardiovascular morbidity and mortality. Recent studies have demonstrated the importance of antihypertensive agents that inhibit the renin-angiotensin-aldosterone (RAA) system to reduce the risk and slow down the progression of renal disease. A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCI or benazepril HCI/hydrochlorothiazide. Other objectives include a comparison of the proportion of patients who progress to overt diabetic nephropathy and the safety of these two combination therapies in these high-risk patients.

KW - ACE inhibitor

KW - Albuminuria

KW - Calcium channel blocker

KW - Diabetic nephropathy

KW - End-stage renal disease

KW - Microalbuminuria

UR - http://www.scopus.com/inward/record.url?scp=13544249937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544249937&partnerID=8YFLogxK

U2 - 10.1038/sj.jhh.1001789

DO - 10.1038/sj.jhh.1001789

M3 - Article

VL - 19

SP - 139

EP - 144

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 2

ER -